Published in final edited form as:

Nat Med. 2014 August ; 20(8): 833–846. doi:10.1038/nm.3647.

Hematopoietic stem cell niche maintenance during homeostasis and regeneration

Avital Mendelson and Paul S Frenette

Abstract

The bone marrow niche has mystified scientists for many years, leading to widespread investigation to shed light into its molecular and cellular composition. Considerable efforts have been devoted toward uncovering the regulatory mechanisms of hematopoietic stem cell (HSC) niche maintenance. Recent advances in imaging and genetic manipulation of mouse models have allowed the identification of distinct vascular niches that have been shown to orchestrate the balance between quiescence, proliferation and regeneration of the bone marrow after injury. Here we highlight the recently discovered intrinsic mechanisms, microenvironmental interactions and communication with surrounding cells involved in HSC regulation, during homeostasis and in regeneration after injury and discuss their implications for regenerative therapy.

Hematopoiesis is a continuous process of blood-cell production occurring through the orchestrated proliferation, self renewal and differentiation of HSCs in the bone marrow followed by egress of mature progeny into the circulating blood^{1–4}. HSCs are the only cells capable of producing all blood cell lineages throughout life⁵. Within the bone marrow exists a tightly controlled local microenvironment, or niche, that regulates the quiescence, proliferation and differentiation of HSCs⁶. Regulatory signals within the niche emanate from surrounding cells in the form of bound or secreted molecules and also from physical cues such as oxygen tension, shear stress, contractile forces and temperature^{4,7,8}. During homeostasis, the majority of HSCs are quiescent⁹ but can become activated to proliferate and differentiate in response to infectious stress such as interferon-mediated signaling^{10–12}.

High-dose chemotherapy or radiation treatment for hematological malignancies such as leukemia, lymphoma or multiple myeloma may induce damage to the bone marrow microenvironment and limit the regeneration and differentiation potential of HSCs by reducing their numbers and causing functional deficits among the remaining HSCs^{1,13–15}. In the 1960s, the promise of stem cell therapy was ignited after Dr. E. Donnall Thomas performed the first successful allogeneic bone marrow transplant, which was a groundbreaking procedure that eventually revolutionized patient care and led to substantial clinical advances in cancer treatment (Box 1). Difficulty in finding suitable adult allogeneic donors along with low stem cell yield from cord blood donation has led to the investigation of stem cell expansion methods (Box 2). However, HSC expansion has been very difficult to achieve because of an inability to maintain these cells in synthetic culture environments that differ from the native bone marrow microenvironment. A promising alternative approach would be to reprogram somatic cells directly into HSCs^{16–18}. However, most transcription factors conferring HSC identity have also been associated with leukemia, raising the potential for malignant transformation using this approach. The success of this cell therapy

also relies on the ability of HSCs to engraft, self renew and differentiate into multiple blood cell lineages⁵. Uncovering safe techniques to promote HSC expansion in vivo without inducing cancerous transformation (Box 3), along with cellular and environmental factors that encourage HSC lodgment while maintaining stemness, could form the basis for new therapeutics and in turn result in expedited regeneration with improved clinical outcomes.

The different cell types of the HSC niche that are essential in HSC maintenance and regeneration are discussed in this Review, along with key regulators of survival and self renewal through intrinsic and extrinsic mechanisms during homeostasis, stress and aging. We propose future directions with promise for advancement in the field and discuss the therapeutic implications of the new players that seem to orchestrate the process of HSC niche regeneration in the bone marrow.

Cellular players of the HSC niche

Technological advances in bone marrow imaging unveiling cellular localization specificities, combined with conditional deletion of crucial regulatory factors from candidate cell types in mouse models, have uncovered several candidates involved in HSC maintenance (Fig. 1)^{19,20}. The bone marrow ‘stroma’ can initiate and maintain hematopoiesis, as demonstrated by the reconstitution of a hematopoietic microenvironment within an ossicle model in which stromal cells are seeded onto a transplanted biomaterial scaffold^{19,20}. Much progress has been made in characterizing the cellular composition of the niche.

Perivascular cells in the HSC niche

Of the cell types that have been suggested to regulate HSC maintenance and regeneration, cells of the vasculature have been the focus of considerable interest. Human bone marrow analyses have suggested that perivascular cells expressing the melanoma-associated cell adhesion molecule (MCAM, also called CD146) are stromal progenitors in the bone marrow²¹ (Fig. 1). A subset of CD146 cells in humans, and a large fraction of perivascular stromal cells in mice, express platelet-derived growth factor receptor- α (PDGFR- α), CD51 (also called ITGAV) and the intermediate filament protein nestin^{22,23}. These cells account for all bone marrow mesenchymal stem and progenitor cells (MSPCs) as measured by colony-forming-unit fibroblastic activity assay²². In addition to being localized near both HSCs and adrenergic nerve fibers, these cells express high levels of genes mediating HSC maintenance and retention, including those encoding the cytokines chemokine (C-X-C motif) ligand 12 (CXCL12) and stem cell factor (SCF)²².

Perivascular stromal cells expressing high amounts of CXCL12, known as CXCL12-abundant reticular (CAR) cells, regulate HSC self renewal, proliferation and trafficking²⁴. Although the exact composition of CAR cells remains unclear, they comprise cells marked by nestin, myxovirus resistance-1 (Mx-1), leptin receptor (Lepr), the transcription factor paired related homeobox-1 (Prx-1) that marks cells of the limb bud mesoderm and the transcription factor osterix (Osx, also called SP7) that is necessary for osteoblast differentiation (as described further below)^{23,25–27}. Stromal cells labeled by Mx1-Cre are also enriched for MSPC activity in culture and label the osteolineage²⁷. Lepr on

perivascular cells is the receptor for the adipocyte-secreted hormone leptin that promotes energy metabolism²⁸. These Lepr⁺ cells have an MSPC phenotype and express SCF and CXCL12 (refs. 26,29). In addition, perivascular Lepr⁺ cells largely overlap with stromal cells marked by nestin-GFP^{22,30} and appear to label a self-renewing mesenchymal population that contributes to adipocyte and bone regeneration^{31,32}.

Endothelial cells in the HSC niche

Endothelial cells line the surface of blood vessels, bridge blood and tissues in the bone marrow and promote HSC maintenance and regeneration after injury^{33,34}. Endothelial cells are ensheathed with pericytes or adventitial reticular cells, including nestin⁺ CAR cells³⁵ (Fig. 1). Studies in embryoid bodies have suggested that endothelial cells and hematopoietic cells derive from a common multipotential precursor cell, the hemangioblast^{36,37}, but there is no evidence in the developing bone marrow that endothelial cells can give rise to pericytes³⁸.

Studies in mice originally defining HSCs by a combination of signaling lymphocytic activation molecule (SLAM)-family surface receptors revealed a preference for HSCs to associate with sinusoidal endothelium in the bone marrow, suggesting a potential regulatory role for the endothelium³⁹. Recent reports have confirmed that bone marrow endothelial cells are able to support hematopoiesis through the expression of essential surface makers, including E-selectin (also called SELE)³⁶, and upregulation of ‘angiocrine’ factors such as fibroblast growth factor 2 (FGF2), delta-like 1 (DLL1), insulin-like growth factor-binding protein 2 (IGFBP2), angiopoietin 1 (ANGPT1), desert hedgehog (DHH) and epidermal growth factor (EGF)^{34,37,40–42}.

Osteoblasts and cell identification challenges

Perhaps the most controversial cellular components of the bone marrow niche are the bone-forming osteoblasts, as initial studies pointed toward their regulatory role in hematopoietic maintenance^{43,44}. However, more recent studies in which CXCL12 or SCF—cytokines that are critical for HSC regulation in mice—were conditionally depleted from mature osteoblasts (marked by osteocalcin (Bglap)-Cre or Col2.3-Cre) showed normal cellularity and lineage composition in the bone marrow and spleen, normal blood counts and a preserved ability to reconstitute in irradiated mice^{25,26,29}, suggesting that osteoblasts do not directly maintain HSCs in the bone marrow.

A stumbling block in the field has been a lack of specificity of the genetic promoters that mark subsets of mesenchymal lineage cells²⁸. For example, although the expression of the osteoblast marker *Osx* is restricted in short-lived osteoblast progenitors in the adult bone marrow, it is also expressed perinatally in immature MSPCs that are long lived in the adult bone marrow^{31,45}. The ability to mark stromal cells with increased precision and differentiate between those present during development and those in postnatal tissues will clarify the cells responsible for promoting HSC maintenance.

Sympathetic nerves

It has been shown that trafficking of HSCs into the bloodstream during steady state is tightly regulated through the circadian release of adrenergic signals from the sympathetic nerves in the bone marrow⁴⁶, suggesting that sympathetic nerves might regulate HSC function. Nestin-expressing MSPCs touch sympathetic nerves directly in the bone marrow and express high levels of HSC maintenance genes during steady state. Electromechanical coupling between noradrenergic nerves and nestin-expressing cells through their $\beta 3$ -adrenergic receptor leads to downregulation of HSC maintenance genes as CXCL12, Angpt1, Kit ligand (Kitl) and vascular cell adhesion molecule 1 (Vcam-1) followed by HSCs egress from the bone marrow^{23,47}. Nonmyelinating Schwann cells, which are wrapped around sympathetic nerves, have also been shown to localize close to HSCs and maintain HSC quiescence by activating transforming growth factor- β (TGF- β)-SMAD signaling⁴⁸.

Macrophages

Macrophages have been added to the pool of key nicheregulating cells given their effect—through an unidentified cytokine—on nestin-expressing niche cells to promote HSC retention by inducing CXCL12 secretion^{49,50}. Macrophages have thus been shown to have a parallel and antagonistic role compared to sympathetic nerves⁴⁹. Interestingly, granulocyte colony-stimulating factor (G-CSF) treatment in mice (which promotes the mobilization of HSCs and production of granulocytes) depletes both macrophages and osteoblastic cells^{50,51} and activates sympathetic neurons to release norepinephrine in the bone marrow microenvironment⁵². As osteoblastic cells do not express the G-CSF receptor, this finding suggests that osteoblast suppression occurs indirectly, possibly through signaling in bone marrow macrophages^{50,51}, and sympathetic activation^{47,52}.

Dispensable HSC niche cell types and negative regulators

Select bone marrow cell types have been shown in genetic animal models to be either dispensable or negative regulators of the HSC niche. After chemotherapy or irradiation, adipocytes have been found in increased numbers in the bone marrow because of adipogenic differentiation of MSPCs⁵³, where their increased presence can hamper hematopoietic recovery² and can be used as a diagnostic indicator of bone marrow aplasia⁵³. Bone-degrading osteoclasts have also been suggested to be dispensable for HSC maintenance in mouse models including op/op mice, which are deficient in a cytokine needed for osteoclast differentiation, and Fos-deficient and Rankl-deficient mice, which are deficient in osteoclasts^{54,55}.

Bone marrow niche signals

The niche must preserve the properties of the stem cell while regulating stem cell maturation and differentiation^{56,57}. A complex milieu of components is responsible for HSC maintenance, including soluble mediators, intrinsic signaling pathways and microenvironmental signals, such as those mediated by adhesion molecules and local oxygen tension, as well as interactions with other cellular niche constituents.

Perivascular-derived SCF and CXCL12 in HSC maintenance

A conditional deletion approach to eliminate key factors from candidate niche cells in animal models has recently defined important regulators of HSC maintenance²⁶. Targeted deletion studies have shown that SCF is expressed by both perivascular and endothelial cells²⁶. These studies also suggested that nestin-expressing niche cells do not contribute to SCF secretion, which seems to contradict previous reports of nestin-expressing stromal cells as an important regulator of the HSC niche²³; this discrepancy is likely due to varying nestin-driven transgenic Cre expression and recombination levels among perivascular cells in the bone marrow²⁶. Indeed, perivascular cells expressing *Lepr* and nestin⁺ reticular cells localize largely together in the bone marrow, but because of the heterogeneity in genetic labeling of perivascular cells, the contribution of this population of cells in SCF secretion will require further analyses^{22,30}. However, *Scf* expression has not been found in bone-lining osteoblast lineage cells marked by *Col2.3-Cre* in either the diaphysis or trabecular bone, indicating that osteoblasts are not an essential source of SCF for HSC maintenance²⁶.

CXCL12 is a niche factor that has been shown to regulate HSC functions such as retention in the bone marrow, quiescence and the ability to induce multilineage reconstitution^{25,29,58}. Initial studies demonstrated that deletion of the CXCL12 receptor, CXCR4, in *Mx1-Cre* mice resulted in substantial reductions in HSC (defined in this study as CD34[−]c-Kit⁺Sca-1⁺Lin[−]) numbers in the bone marrow because of an enhanced exit from quiescence²⁴. Deletion of CXCL12 from CAR cells using *Osx-Cre* markedly reduced CXCL12 expression but showed no effect on HSC maintenance and led to mobilization of HSCs to the blood²⁵. Similar results were observed with *Lepr-Cre* deletion²⁹, suggesting that reticular cells around sinusoids are crucial for HSCs in bone marrow.

In contrast, the *Prx1-Cre* deletion strain in which CXCL12 is deleted more broadly in the appendicular skeleton revealed a role for CXCL12 expressed by these stromal cells in maintaining HSC repopulating activity and quiescence^{25,29}. Given the recently reported role of arterioles in regulating HSC quiescence and the high levels of CXCL12 expression in periarteriolar nestin-GFP⁺ cells³⁰, further studies will be needed to define the stromal subsets forming HSC quiescent niches. However, deletion of CXCL12 with nestin-Cre has not revealed any defect in HSC frequencies, suggesting that recombination did not occur in nestin-GFP⁺ cells even though these cells are probably a major contributor of CXCL12 content in bone marrow. By contrast, deletion of CXCL12 in endothelial cells using *Tie2-Cre* revealed minimal defects in HSC numbers and competitive reconstitution abilities^{25,29}.

Conditional deletion of CXCL12 in osteoblasts (*Col2.3-Cre* or *Bglap-Cre*) did not result in any HSC defects^{15,33}. However, deletion with *Col2.3-Cre* resulted in reduced levels of B and T cell reconstitution and depletion of early lymphoid progenitors in the bone marrow²⁹. These results argue that the mesenchymal cells committed to the osteoblast lineage are dispensable for HSC maintenance but may regulate lymphoid progenitors.

Notch and HSC maintenance

The Notch pathway plays an important part in many developmental processes, and it has been suggested to regulate many adult stem cell fate decisions (reviewed in refs. 59,60).

Although Notch signaling has been found to regulate HSC recovery after stress in mice, it remains under debate whether canonical Notch signaling contributes to HSC maintenance or whether this signaling pathway is dispensable^{37,60–63}.

Expression of Notch receptors early in hematopoiesis may be involved in cell differentiation decisions and may be used to identify specific progenitor cell types with a predetermined cell fate⁶¹: Notch1 was found to promote T cell commitment and has been shown to specify megakaryocyte fate, whereas Notch2 marked primarily erythroid progenitor cells^{61,62,64}. Notch1 and Notch2 receptors have also been found to promote the expansion of long-term repopulating HSCs (LT-HSCs; CD34–FLT3–Lin–c-Kit+Sca-1+) while preserving self-renewal ability^{34,37}. Short-term repopulating HSCs (ST-HSCs; Lin–CD34+Sca-1+c-Kit+) secrete vascular endothelial growth factor A (VEGF-A) when exposed to soluble SCF in vitro, which in turn stimulates the translocation of the Notch ligand Jagged-2 (Jag2) to the endothelial cell surface³⁷. Jagged-2 supports the expansion of STHSCs through expression of Notch1 and Notch2 receptors³⁷. After conditional deletion of Jagged-1 in endothelial cells, there were reductions in the numbers and function of LT-HSCs during homeostasis and during hematopoietic regeneration after irradiation, suggesting that this Notch ligand is required to maintain the quiescence and self renewal of HSCs⁶⁵.

Although these findings suggest that canonical Notch signaling promotes HSC self renewal and maintenance, other studies have suggested that it may also be dispensable^{63,65,66}. Using a dominantnegative approach to inhibit Notch signaling in hematopoietic progenitors from mice, LT-HSCs were maintained after transplantation, suggesting that Notch signaling is dispensable⁶³. Furthermore, the Notch ligand Dll4 on erythroblasts has been shown to promote premature T cell differentiation in HSCs unless this signal is suppressed by leukemia/lymphoma related factors that are also released by erythroblasts to promote self renewal⁶⁷.

The difficulty in resolving opposing results regarding the role of Notch in hematopoiesis may lie in the innate complexity of the signaling pathway and methodologies used to evaluate its function. For example, inhibiting one protein required for the transcriptional activation of Notch signaling may result in the activation of compensatory pathways⁶⁸. Resolution of the specificity of the cell types targeted for genetic deletion, the levels of Notch pathway inhibition and a study of the pathways under comparable conditions will be required to determine the extent to which Notch is necessary for HSC regulation.

A complex and unresolved role for Wnt in hematopoietic regulation

Wnt, similar to Notch, is another pathway that has been demonstrated to regulate the development of various tissues, including hematopoietic tissues (reviewed in ref. 69). Initial β -catenin (Ctnnb1, an important component of the Wnt pathway) gain-of-function studies investigating the role of canonical Wnt demonstrated that activation of β -catenin in HSCs led to HSC expansion in vitro while maintaining an immature HSC state and promoting trilineage reconstitution^{70,71}. Conversely, an opposite result indicated that the constitutive activation of β -catenin using Mx1-Cre in mice led to induced cell cycle entry, impaired differentiation, exhaustion and reduced multilineage reconstitution after transplantation followed by death^{72,73}. The different methods used to constitutively activate β -catenin in

the aforementioned studies potentially led to varying Wnt signaling levels in HSCs and might account for the observed discrepancies.

Loss-of-function studies in mice found that deleting the canonical Wnt ligand Wnt3a led to lower HSC and progenitor cell numbers in the fetal liver, decreased self renewal and reduced long-term repopulation ability⁷⁴, supporting a role for canonical Wnt in regulating HSC self renewal, although the specific underlying mechanism has not yet been uncovered. Conditional deletion of β -catenin using Vav-Cre or specific overexpression of a negative regulator of canonical Wnt, Dkk1, in osteoblastic cells (Col2.3-Cre) in vivo also resulted in decreased hematopoietic reconstitution after transplantation and further confirmed the role of Wnt in HSC self renewal^{74–77}. However, conditional deletion of both β -catenin and γ -catenin in Mx1-Cre mice did not affect self renewal or hematopoiesis after transplantation^{78,79}. Despite deletion of both β -catenin and γ -catenin, Wnt signaling remained present, suggesting that a compensatory β -catenin homolog may exist^{79,80}.

Although the majority of studies have investigated canonical Wnt, the noncanonical Wnt pathway has also been suggested to affect HSC behavior. The noncanonical Wnt ligand Wnt5a has been suggested to inhibit canonical Wnt signaling, inhibit cell proliferation in vitro and increase the repopulating ability of HSCs in a mouse model⁸¹ by acting through the receptor-like tyrosine kinase (Ryk) receptor⁸². LT-HSCs have been reported to express the members of noncanonical Wnt signaling flamingo (Fmi, also called Celsr) and frizzled 8 (Fzd8), which promote quiescence during homeostasis by preventing nuclear localization of nuclear factor of activated T cell (NFAT), suppressing interferon- γ (IFN- γ) expression and antagonizing canonical Wnt signaling⁸³. Stress-mediated activation of HSCs in mice may result in the repression of noncanonical Wnt signaling and enhanced canonical Wnt signaling, leading to HSC activation⁸³.

Generation of a gradient of canonical Wnt signaling levels confirmed the previously noted differences in HSC behavior, where HSCs favored low levels of canonical Wnt signaling, leading to the maintenance of an immature phenotype and enhanced long-term repopulation capacity as opposed to moderate and high levels of Wnt signaling, which impaired the ability of HSCs to repopulate⁸⁴. Whereas complete loss of Wnt signaling resulted in impaired self renewal, low levels of Wnt signaling led to HSC maintenance, demonstrating a high sensitivity to dosage, which must be considered for potential clinical translation. Although the role of Wnt in HSC maintenance remains unresolved, conditional deletion of canonical and noncanonical Wnt regulators from key niche cells, such as perivascular stromal cells, could further clarify its role.

N-cadherin

Original reports of HSCs homing near N-cadherin (Cdh2)- expressing osteoblasts led to the idea that N-cadherin expression on HSCs is responsible for homophilic binding to N-cadherin- expressing osteoblasts⁴³. There has been considerable effort spent on elucidating the role of this adhesion receptor in the HSC niche. Low as compared to intermediate levels of expression have been suggested to mark a more active or reserved state, respectively⁸⁵, and overexpression of N-cadherin in hematopoietic stem progenitor cells (HSPCs) reduced their proliferation in vitro⁸⁶. However, conditional deletion of N-cadherin in HSCs using

Mx1-Cre mice revealed normal HSC frequency and an unaffected ability to reconstitute irradiated mice with primary and secondary transplantations, suggesting that N-cadherin is not required to cell-autonomously maintain HSCs⁸⁷. Other studies that have conditionally deleted N-cadherin in osteolineage cells have not found an HSC phenotype^{88,89}. These studies thus suggest that N-cadherin is dispensable for HSC function, although it could potentially mark an HSC subset or be capable of modulating HSC function when its expression is enforced. Because N-cadherin is highly expressed on HSC niche cells²³, it may regulate MSPC differentiation, as suggested by a reduction of mineralized bone when deleted in the osteolineage⁸⁹.

TGF- β . Various sources of TGF- β have been linked to HSC maintenance in the bone marrow niche. Nonmyelinating Schwann cells that wrap nerves in the bone marrow can secrete TGF- β activator molecules into the niche to induce TGF- β –SMAD signaling in HSCs, which contributes to maintenance and self renewal through increased phosphorylation of Smad2 and Smad3, causing HSC dormancy⁴⁸. TGF- β 1 was also found to stimulate myeloid-biased HSCs to proliferate while inhibiting lymphoid-biased HSCs⁹⁰. TGF- β blockade in mice revealed that TGF- β inhibition shortly after chemotherapy results in increased hematopoietic cycling and accelerated hematopoietic reconstitution, whereas inhibition during homeostasis did not induce HSPC cycling⁹¹, suggesting that blocking TGF- β signaling during regeneration could enhance hematopoietic recovery. Cripto (also called TGDF1), a protein that blocks TGF- β signaling, binds to the GRP78 (also called HSPA5) receptor on hypoxic HSCs and activates the PI3K-Akt pathway, which results in the maintenance of HSCs located in the ‘endosteal niche’. Blocking Cripto-GRP78 signaling with the N-20 blocking antibody led to mobilization of HSCs from the endosteal region to the central marrow area but did not change HSC frequency in the bone marrow, peripheral blood or spleen, indicating that local mobilization was induced but peripheral circulation was not⁹². Endosteal cells expressing Cripto on their cell surface included Alcam–Sca-1+ and, to a lesser extent, Alcam+Sca-1– cells⁹². Taken together, these niche-regulating soluble factors and signaling pathways implicate vascular niches as regulators of HSC self renewal and maintenance.

Other niche factors regulating HSC function

Additional secreted factors from the bone marrow microenvironment have been shown to regulate HSC maintenance in vivo. Tie2-expressing HSCs associate closely with angiopoietin 1–expressing stromal cells, and this interaction has been shown to enhance the adhesion of HSCs to osteoblastic cells through an upregulation of integrin β 1, leading to HSC quiescence, stem cell renewal and protection from myelosuppressive stress⁹³. Given the role of MSPCs in the HSC niche, it will be important to define which cells of the microenvironment secrete angiopoietin 1.

Pleiotrophin secretion by bone marrow sinusoidal endothelial cells regulates HSC maintenance through binding and inactivating phosphatase activity induced by the transmembrane protein tyrosine phosphatase receptor type Z (PTPRZ) and retention in the bone marrow in vivo through the CXCR4-CXCL12 axis^{41,94}. Interestingly, the pleiotrophin contribution from various primary stromal cell lines prepared from the aorta-gonad-

mesonephros region of mouse embryos was also found to mediate hematopoietic regeneration⁹⁴, suggesting that broad sources of pleiotrophin may yield HSC maintenance and regeneration and that their individual contributions should be further resolved. Plastic-adherent bone marrow stromal cells are able to secrete the retinaldehyde-inactivating enzyme CPY26 to sustain low levels of retinoic acid signaling that would otherwise mediate terminal differentiation and promote a primitive HSC phenotype and HSC function and self renewal, as assessed in vitro and in vivo⁹⁵. Other cell types found in the bone marrow, such as endothelial cells and osteoblasts, also express CYP26, but their individual roles in maintaining low levels of retinoid acid signaling have not been confirmed^{95,96}.

Location of the niche

With the discovery of specific HSC surface markers, improved histological imaging capabilities in both live mice and fixed tissues and conditional deletion of HSC regulatory molecules from specific niche cells, the original view that osteoblasts regulate HSC maintenance and differentiation in the bone marrow niche has been revised, and the relevant role of perivascular cells has been uncovered^{30,97}. Several imaging studies have suggested that HSCs may lodge in specific areas of blood vessels, possibly because of endothelial adhesive molecules⁹⁸. Homeostatic HSCs are homogeneously distributed, whereas transplanted HSCs preferentially home to the trabecular bone region. These HSCs seem to have enhanced regenerative and self-renewal capacities compared with those that localize to the diaphysis region⁹⁹.

The use of intravital microscopy imaging of the mouse calvarium recently revealed that after injection into nonirradiated mice, all HSCs and progenitor cells homed and localized very close (within 16 μm) to the vasculature¹⁰⁰ (Fig. 2). After transplantation into irradiated mice, however, most HSCs were found closer (within 15 μm) to the endosteum, where they were able to generate all peripheral blood lineage cells¹⁰⁰. A subsequent study using a fiber optic imaging system showed that transplanted LT-HSCs were able to localize nearby vascular structures within 5 h of transplantation, regulated in part by VCAM-1 expression on endothelial cells¹⁰¹. More recent image analyses using laser-scanning cytometry, which enabled quantitative imaging of fluorescently labeled cells within mouse tissue sections, revealed that primitive progenitors (Lin[−]CD48[−]CD41^{lo}−c-Kit⁺) were enriched in the endosteal region and were associated with blood vessels⁹⁷.

High-resolution imaging in combination with genetic labeling approaches have also unveiled a structural compartment, called the hemosphere, located in the metaphyseal region near the growth plate consisting of endothelial, mesenchymal and hematopoietic cells, which has been suggested to promote rapid HSC proliferation and clonal expansion¹⁰². Whole-mount confocal immunofluorescence to image mouse bone marrow further defined the association between HSCs and the vascular structures, showing that quiescent HSCs (defined as Ki-67[−] or BrdU label-retaining CD150⁺CD48[−]Lin[−]CD41[−] cells) localized mainly with small arterioles of the endosteal region, which were ensheathed by NG2 (CSPG4)⁺ pericytes³⁹. After HSC activation, however, these cells moved away from the NG2⁺ periarteriolar niche to the Lepr-expressing perisinusoidal niche³⁰. Although most

proliferating HSCs are associated with sinusoids, the density of these vessels is such that the short distances were not statistically different from a random placement.

Although most studies used a 12-cell diameter or a distance of 100 μm from the bone to define the endosteum, three-dimensional imaging has shown that HSCs are concentrated in a much larger endosteal fraction³⁰. About 80% of HSCs lie within 50% of the distance (on average $\sim 220 \mu\text{m}$) to the bone surface, whereas only 20% are found within 50% of the distance toward the central vein (Fig. 2). It thus remains unclear how the bone influences this HSC distribution, as other confounding structures (for example, arterioles) are also concentrated in this area.

HSCs and stress

HSCs may be challenged by diverse sources of stress, including oxidation, anemia, hypoxia, radiation, cytotoxic chemotherapy and inflammation, which can disrupt homeostasis and impair regeneration^{103,104}. Ionizing radiation and chemotherapy, which are commonly used to treat hematopoietic malignancies and leukemia, invariably lead to bone marrow injury and alteration in cell composition¹. After chemotherapy there is a progression of blood cell death based on the innate lifespan of the cell, with granulocytes preceding platelets followed by erythrocytes¹⁰⁵, and chronic effects in bone marrow cells that include reductions in the amounts of progenitor cells that have increased cycling¹⁰⁵.

Irradiation

Effects on the bone marrow from irradiation resemble those induced by chemotherapy, including chronic toxicity that can affect the dynamics of bone marrow cell production, maturation, trafficking and lifespan¹⁰⁵. Repeat exposure to radiation can lead to the development of cancer, weakened hematopoietic mobilization and delayed hematopoietic reconstitution, leading to impaired bone marrow regeneration after transplantation¹⁰⁶. HSCs are sensitive to radiation and react by increasing apoptosis in a dose- and time-dependent manner, which can be attenuated by VEGF-induced expression of myeloid cell leukemia-1 (MCL1) in hematopoietic progenitor cells^{107,108}. Administration of thrombomodulin or activated protein C (aPC) within 24 h after lethal irradiation in mice has been reported to have a radiomitigating effect and result in improved hematopoietic recovery¹⁰⁹. Although the underlying cellular and molecular mechanisms remain to be fully uncovered, a subsequent study demonstrated that aPC can promote antiapoptosis through binding to the protein C receptor on HSCs¹¹⁰. Additionally, a group of small-molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6 can also mitigate the hematopoietic toxicity induced by radiation by promoting pharmacological quiescence of early hematopoietic stem and progenitor cells in the bone marrow¹¹¹. These options may present alternative avenues to mitigate the toxicities of irradiation.

The shift from survival to initiation of apoptosis after irradiation of HSCs is regulated by the B cell CLL/lymphoma 2 (BCL-2)-family proteins and p53 (refs. 112,113). The p53-interacting protein known as apoptotic stimulating protein of p53 (ASPP1 or PPP1R13B) is responsible for altering the transcriptional activity of p53 to promote apoptosis¹¹³. Chronic inflammation, a long-term effect of ionizing radiation, induces increased amounts of plasma

tumor necrosis factor- α (TNF- α), IFN- β , interleukin-6 (IL-6) and C-reactive protein, which can suppress the recovery of residual HSCs¹¹⁴. Regeneration therapies after radiation could therefore potentially benefit from treatments aimed at reducing inflammation.

Oxidative stress

Oxidative stress is the result of an overabundance of cellular reactive oxygen species (ROS) accumulation formed by the partial reduction of oxygen or a defect in the antioxidant protection mechanism^{115,116}. The ability of hematopoietic tissues to maintain redox status is crucial to maintaining normal hematopoiesis¹¹⁵, as free radicals and ROS produced by high doses of radiation alter HSC repopulating ability and damage the bone marrow vasculature^{13,117}. Substantial delay in DNA double-strand break repair after irradiation leads to DNA damage¹¹³, which can be exacerbated by the DNA damage caused by increased HSC proliferation after radiation¹¹⁸. ROS can activate DNA damage response pathways mediated by p53, ATM, 53BP1 (TP53BP1), CHK2 and FOXO3a, which in turn activate the HSC cell cycle inhibitors p16INK4a, p14ARF and p21CIP1, promoting senescence and loss of stem cell function¹¹⁸. Therapeutic strategies aimed at reducing excessive ROS accumulation after radiation may also provide a path to expedite recovery.

Lessons from radioresistant cells

Although Lessons from radioresistant cells. Although the majority of HSCs are adversely affected by irradiation, radioresistant cell populations also exist in the bone marrow. For example, mature megakaryocytes localize near the trabecular surface after irradiation, where they produce growth factors that stimulate increased cycling of CD45⁺ nestin-expressing MSCs, leading to their differentiation into preosteoblasts, potentially increasing hematopoietic stem cell number as well¹¹⁹. Numerous studies have indicated the effectiveness of various cytokines at stimulating radioresistant cell populations for promoting hematopoietic recovery in both animal models and humans¹²⁰. In particular, administration of a single dose of SCF, FLT3 ligand, thrombopoietin (TPO) and IL-3 within 2 hours after irradiation effectively led to reduced cytopenia and improved hematopoietic recovery in mice and nonhuman primates and could potentially serve as a treatment method for patients after accidental or intentional radiation exposure^{121,122}. Whether other niche-regulating stromal cells are affected by radiation stress remains unknown, but their identification could potentially uncover new target cell sources to increase bone marrow function in patients after irradiation.

Regeneration of the HSC pool after injury

Substantial efforts have been dedicated toward uncovering the mechanisms regulating HSC niche maintenance, yet the regenerative process that takes place after hematopoietic injury remains more elusive (Fig. 3). Various signaling pathways implicated in homeostasis have also been shown to be involved in regeneration and are mediated in part by the bone marrow vasculature.

Notch signaling

Notch signaling appears to be important for HSC regeneration, as it has been shown that angiogenic factors released by endothelial cells stimulate Notch ligands to prevent HSC exhaustion after myeloablation from lethal irradiation³⁷. Activation of the Akt-mTOR pathway in endothelial cells also promotes hematopoietic stem and progenitor cell regeneration through regulation of angiocrine factors³⁴. In addition, expression of the canonical Notch ligand Jagged-1 by endothelial cells also supports hematopoietic regeneration by balancing the levels of self renewal and differentiation to prevent premature HSC exhaustion⁶⁵. In HSCs, Notch signaling activation enhances megakaryocyte production and platelet formation by interacting with Dll1 ligand expressed by OP9 stromal cells⁶⁴, whereas Notch2 signaling through Jagged-1 enhances the generation of short-term repopulating multipotent progenitor cells and long-term HSCs after myeloablation while hindering myeloid differentiation⁶².

Regulating apoptosis

A recent investigation further highlighted the regulatory effects of endothelial cells on HSC regeneration after radiation injury¹²³. In mice, deletion of the proapoptotic genes Bak and Bax in Tie2-expressing HSCs and endothelial cells prevented their depletion after irradiation and resulted in radioprotection of HSCs¹²³. Deletion of Bak and Bax in VE-cadherin-Cre mice, which only targets a small subset of HSCs, led to an increase in 15-day survival but resulted in no statistical difference in 30-day survival compared to VE-cadherin-Cre+ Bakflox/+; or Baxflox/+ and VE-cadherin-Cre- mice¹²³. These results indicate that the hematopoietic response to radiation is mediated by HSC-autonomous effects as well as endothelial cell-mediated mechanisms¹²³. In addition, these findings confirm previous studies showing that reducing radiation-induced apoptosis of HSCs through repression of the proapoptotic protein PUMA (BBC3) can promote HSC recovery⁴⁰.

TGF- β

During regeneration after myelosuppression from chemotherapy, there is transient activation of the TGF- β pathway in HSCs⁹¹, and its blockade in this setting—but not during homeostasis—enhances hematopoietic reconstitution, hindering the ability of hematopoietic cells to fall back into a quiescent state⁹¹. Clinical use of TGF- β inhibitors could result in enhanced multilineage hematopoietic regeneration after myelosuppressive chemotherapy, but the timing of delivery must be carefully controlled.

Cytokines

Cytokine signaling is also an essential component of the cascade regulating HSC regeneration. A cytokine screen of bone marrow fluid from mice with endothelial cells resistant to irradiation-induced apoptosis identified EGF as a factor promoting radioprotection of HSCs⁴⁰. EGF receptor signaling in HSCs was able to directly induce multilineage regeneration of a pool of HSCs that survived after myelosuppressive injury by suppressing the proapoptotic protein PUMA, with a skewing toward myeloid recovery over T lymphoid lineages⁴⁰.

The cytokine pleiotrophin secreted from stromal components has been shown regulate the balance between myeloid and lymphoid cell regeneration after myelosuppression through a β -catenin-independent increase in expression of cyclin D1 (CCND1) and C/EBP α (CEBPA) in Lin-Sca-1+c-Kit⁺ (LSK) cells⁹⁴. Associated HSC regeneration after myeloablation due to pleiotrophin may also be mediated through Notch signaling⁹⁴. Additionally, VEGF is able to induce HSC survival by inhibiting apoptotic death of HSCs caused by irradiation and through an internal autocrine loop mechanism in which only inhibitors that penetrate the intracellular region are able to block receptor signaling, as opposed to surface-binding antibodies^{124,125}. FGF secreted by megakaryocytes promotes HSC proliferation and mobilization through FGF receptor-1 expressed by hematopoietic stem and progenitor cells, which stimulates nuclear factor κ B (NF- κ B) transcription and upregulation of CXCR4 in response to bone marrow damage¹²⁶. The inflammatory cytokine IFN- γ has been shown to stimulate quiescent HSCs to proliferate and produce an increase in downstream progenitors while preventing HSC exhaustion in homeostasis and during infectious stress¹², although other studies have suggested that IFN- γ impairs HSC maintenance¹²⁷. Thus, taken together, these studies suggest that distinct sets of cytokines may have more apparent functions during regenerative stress.

Extracellular matrix proteins

A number of extracellular matrix (ECM) and cell adhesion proteins have been implicated as having effects on regeneration. The preference of HSCs to engraft at the endosteal niche as compared to a more central localization is promoted by the calcium-sensing receptor (CaR) expressed on HSCs, leading to enhanced CXCR4 signaling and increased HSC adhesion to collagen I, a predominant component of the bone marrow ECM that is released by mesenchymal cells¹²⁸. E-selectin, a cell-adhesion molecule expressed constitutively by bone marrow endothelial cells, promotes HSC adhesion to the vascular niche, resulting in their proliferation, may be expressed at higher levels on endothelial cells located near the endosteal region compared with those near the central vein and is found at increasing levels during recovery from irradiation³⁶. Deletion of E-selectin in vivo enhances HSC quiescence and self renewal and HSC survival after chemotherapy or radiation, accelerating blood neutrophil recovery. Although the counterreceptor on HSCs remains unidentified, E-selectin ligand-1 (ESL-1) seems to be a prime candidate, as it mediates mainly E-selectin binding and the homing of LSK cells¹²⁹.

The ECM protein tenascin C (TNC), which is expressed in stromal and endothelial cells, is notably upregulated during hematopoietic recovery after myeloablation through binding with integrin α 9 on the surface of hematopoietic stem and progenitor cells, leading to increased expression of the cell-cycling genes cyclin D1 and cyclin E1 (ref. 130). After transplantation into nonirradiated mouse recipients, increased production of the glycosaminoglycan hyaluronan through Has3 synthase by the blood vessels within the endosteum induces transendothelial migration and HSC homing to the trabecular metaphysis region⁹⁸. Robo4 expression on HSCs regulates cell location through interaction with the slit family of secreted ligands and cooperates with the CXCR4 receptor in HSCs to mediate HSC anchorage to bone marrow niches. Robo4 is also expressed by endothelial cells and shares a pathway that is regulated by VEGF receptors, which has been shown previously to

promote hematopoietic reconstitution by repairing irradiation-induced damage to the sinusoidal endothelium^{42,131}. Thus, Robo4 expression by endothelial cells might also affect hematopoietic reconstitution ability¹³¹.

Niche cell populations in regeneration

Select niche constituents have been shown to directly promote hematopoietic regeneration. Macrophages contribute to recovery from anemia as well as the pathological progression of polycythemia vera and β -thalassemia by modulating erythroid proliferation and differentiation by promoting signaling pathways complementary to Epo-EpoR-Jak2 signaling and by providing iron to regulate erythropoiesis^{132,133}. Megakaryocyte mobilization from the endosteal region to the vascular niche occurs through VEGF-A, which acts with VEGFR1 to induce megakaryocyte maturation and platelet production, leading to CXCR4 upregulation and translocation in the bone marrow¹³⁴.

Vascular damage after myelosuppressive therapy prevents relocation of megakaryocytes, leading to reduced platelet recovery^{134,135}. Sinusoid-associated nestin-GFPdim MSCs are largely destroyed after chemotherapy, whereas nestin-GFPbright MSCs wrapping arterioles are more quiescent and are chemoresistant. Conditional deletion of NG2-expressing pericytes wrapping the arterioles resulted in cycling of HSCs, indicating that HSC quiescence is maintained near arterioles. The affinity for HSCs and nestin-GFPbright MSCs to colocalize and maintain a quiescent state during homeostasis suggests the potential for arterioles to have an important role in regulating HSC regeneration³⁰. Furthermore, chemotherapy-induced nerve injury has been shown to slow down hematopoietic recovery unless neuroprotection occurs, promoting the survival of nestin+ cells and endothelial cells after chemotherapy through deletion of the tumor suppressor gene p53, production of 4-methylcatechol-induced nerve growth factor (NGF) or injection of glial-derived neurotrophic factor (GDNF), leading to improved hematopoietic recovery¹. This vital function of the sympathetic fibers for promoting the survival of niche constituents further points toward arterioles, which are ensheathed with nerve fibers, as a key structural basis for initiating reconstitution and hematopoietic regeneration (Fig. 3).

The aging effect

All HSC progeny are prone to the effects of aging¹³⁶. Aging negatively influences the maintenance of HSC function by increasing HSC proliferation and promoting a biased differentiation potential (Fig. 4)^{137,138}. Transplantation of HSCs from aged mice into younger recipients revealed that the aged cells had a 50% lower chance of homing to the bone marrow and were less likely to contribute to hematopoiesis compared to the younger cells¹³⁶. Additionally, differentiation is biased toward the myeloid lineage both in clonal analyses and during transplantation after myeloablation, leading to reduced blood cell reconstitution¹³⁶. This could also alter immune system function, leading to an increased risk among the elderly for infectious diseases, autoimmune diseases, anemia and ineffective vaccinations^{136,137,139–142}. Although the exact mechanism has not yet been defined to explain this phenomenon, two potentially complementary viewpoints have been suggested^{136,143}.

Intrinsic regulation of aging

One perspective on aging supports an intrinsic regulation of HSCs that results in increased differentiation biased toward the production of common myeloid progenitors and a decreased ability to produce common lymphoid progenitors and erythroid cells^{142–145}. These intrinsic changes lead to stem cell exhaustion and decreased hematopoietic cell repopulation capacity, as well as reduced survival rates¹⁴⁶. A downregulation of the cell adhesion molecules $\alpha 4$, $\alpha 5$ and VCAM on aged HSCs leads to reduced adhesion to bone marrow stromal cells expressing high levels of HSC maintenance genes, which might account for the observed increase in mobilization in aged mice^{138,141,147}. TGF- $\beta 1$ has been reported to enhance myeloid-biased HSC differentiation while inhibiting lymphoid-biased HSCs⁹⁰. CD41 cell surface expression has been found to increase in aged stem cells that are capable of long-term repopulation and survival and also to shift these cells toward a myeloid lineage bias¹⁴⁸. Aryl hydrocarbon receptor (AhR), a helix-loop-helix transcription factor with a role in immunity, has been shown to have a role in HSC regulation in aging, as its depletion led to premature HSC exhaustion, downregulated self-renewal potential in competitive repopulation and serial transplantation and development of a myeloproliferative disorder¹⁴⁹.

The deletion from HSCs of Ott1 (one twenty two-1, also called Rbm15), a protein that has been shown previously to regulate hematopoiesis, pre-B cell development and competitive reconstitution¹⁵⁰, induced a phenotype similar to that observed in age-associated physiological changes, including loss of quiescence during stress, increased bias toward myeloid cell production, elevated ROS levels, increased mitochondrial mass, DNA damage and increased activation of NF- κ B and p38 MAPK¹⁵¹. Additionally, HSCs lacking activated leukocyte cell adhesion molecule (ALCAM) also displayed a phenotype that was consistent with aging, with a diminished capacity for long-term repopulation¹⁵².

The chromatin regulator Satb1 is induced during differentiation from HSCs to lymphoid lineage cells, and its expression levels decrease in aged HSCs¹⁵³, suggesting that its expression levels could potentially be used as an indicator of immunosenescence and aging. There are increased levels of CDC42, a RhoGTPase that regulates cell-cell contact, cell-ECM adhesion and cell polarity¹⁴⁴, in aged mice, leading to the onset of an aging phenotype that includes lineage skewing, decreased regenerative capacity, impaired homing, loss of cell polarity and increased mortality^{144,154}. HSC aging was recently attributed to the shift from canonical to noncanonical Wnt signaling as a result of increased Wnt5a expression in aged HSCs, leading to the activation of CDC42 (ref. 155). Interestingly, inhibition of Wnt5a in LT-HSCs using shRNA in aged mice led to a phenotype that was characteristic of young HSCs and could potentially form the basis for rejuvenation therapy¹⁵⁵.

ROS can also induce intrinsic cellular changes leading to replicative senescence and aging¹⁴⁶. After oxidative stress, increased ROS levels seem to associate with decreased levels of thioredoxin-interacting protein (TXNIP), FOXO depletion, p38-mTOR activation and telomere shortening that leads to DNA damage^{115,146,156–158}. After DNA damage, cell regulation occurs, leading to cell cycle checkpoint activation, apoptosis or

differentiation controlled by p16INK4a, BCL-2, BATF and p53 (refs. 113,159–162). Of these proteins, BCL-2 and p53 have been established as important regulators of apoptosis¹¹³. In addition to its role in apoptosis, p53 has a vital role in preventing the expansion of abnormal cells and is involved in numerous DNA damage repair pathways such as activation of cell cycle checkpoints and suppression of homologous recombination^{113,115}.

DNA damage restricted to the mitochondria of mice containing defective mitochondrial polymerase- γ also induces a phenotype similar to premature HSC aging that is characterized by anemia, lymphopenia and myeloid lineage skewing; however, these mice display variations in gene expression profiles compared to true aged mice and show little effect on the size of the HSC pool¹⁵⁹. Thus, although mitochondrial DNA mutations might be a contributing factor in physiological aging, they may not be the primary driver of somatic stem cell aging¹⁵⁹. The overlapping HSC phenotype between irradiation stress and aging-induced cellular changes (derived from ROS activation and subsequent DNA damage) indicates that irradiation may induce premature aging. This concept, however, needs further validation.

Extrinsic regulation of aging

Another model of aging suggests an extrinsic regulation mediated by the microenvironment, which induces a common myeloid progenitor bias rather than effects caused by age-specific intrinsic HSC changes¹⁴⁶. In favor of a microenvironmental balance, HSCs have been shown to change location relative to the bone surface in aged mice compared to young animals and localize further away from the endosteum¹⁶³. Furthermore, given that bone marrow endothelial cells have been shown to promote HSC regeneration in part through upregulation of adhesion proteins, the reduction in HSC adhesion to bone marrow stromal cells with aging could account for the decrease in self-renewal ability among aged HSCs. Aged mice also had a decreased number of mesenchymal progenitor cells located near the endosteal surface compared to young mice, potentially hampering the ability of HSCs to remain quiescent¹⁶⁴. The proinflammatory cytokine CCL5, which is secreted by stromal or differentiated blood cells, may be another important factor promoting extrinsic stem cell regulation, as it induces myeloid lineage skewing in aged HSCs and is associated with a decrease in lymphoid progeny¹⁶⁵. Adipocytes are increasingly present in the bone marrow microenvironment with age, which negatively regulate hematopoiesis and delay engraftment⁵³. Systemic increases in the plasma protein concentration of several secreted signaling factors in aged mice could further contribute to the age-associated changes within the bone marrow niche, although the underlying mechanisms remain to be elucidated¹⁶⁶.

Further investigations into the interplay between the intrinsic and extrinsic mechanisms involved in regulating HSC aging could lead to a therapeutic basis for promoting stem cell rejuvenation. Intrinsic changes often yield phenotypes that are complementary to extrinsic aging effects, indicating that the HSC aging phenotype involves a complex array of factors and a line of communication between the HSC and its niche.

Future directions

Enormous progress has been made in elucidating the key cellular players responsible for regulating the hematopoietic niche, but many unresolved areas remain. Powerful imaging technologies have led to a more comprehensive understanding of HSC localization, pointing toward vascular niches as the favorable anatomic compartment required for hematopoietic regeneration. Although these technological advances have clarified certain longstanding questions, our understanding of the bone marrow stroma remains nascent, as recently identified genetic markings, including *nestin*, *Lepr* and *Osx*, label a small fraction of bone marrow stromal cells. Thus, the origin, identity and function of the majority of stromal cells are unknown^{167,168}. The identification of markers to define the subsets of stromal cells will improve our understanding of HSC maintenance regulation.

Hematopoietic aging—through both intrinsic and extrinsic mechanisms—invariably impairs regenerative potential; however, rejuvenation remains a treacherous road that may cross paths with malignant transformation. The advent of induced pluripotent stem cells poses a great advance in this regard¹⁶⁹, demonstrating that cellular differentiation might be reversible. Pharmacological approaches to targeting age-associated intrinsic pathways or locally targeting extrinsic circulating cytokines could lead to new rejuvenation strategies. Perhaps the HSC subpopulations within the bone marrow do not uniformly age, leading to the protection of certain subsets as reserves. Thus, therapeutics to selectively target and eliminate the population of malfunctioning aged HSCs could lead to a ‘rejuvenation wave’ of transient replication and repopulation of the bone marrow with the remaining primitive HSCs.

Expanding HSCs for regenerative cell therapy is an unmet challenge in need for advancement (Box 1). Currently, numerous culture conditions with variations in growth medium, cytokine or chemical compound supplementation, cocultured cells and varied oxygen tension are used to expand and differentiate HSCs; however, these techniques have also resulted in poor bone marrow engraftment in allogeneic transplantations in mice and humans^{170–173}. Understanding how to generate engraftable HSCs from pluripotent stem cells may give insight into the developmental cues uncoupling HSC quiescence and self renewal. Improved in vitro models of bone marrow niches through combinations of biomimetic biomaterial substrates, bioreactors, coculture of multiple candidate niche cells and real-time imaging could give rise to a new understanding of niche cell functionality *ex vivo*¹⁷³. This knowledge, combined with an improved understanding of the molecular mechanisms controlling HSC self renewal, could potentially lead to new expansion protocols.

Improving the regeneration capacity of HSCs in patients with recurring cancers subjected to irradiation or chemotherapy is another area in need of improvement. Chemotherapeutic treatment for patients with cancer causes acute bone marrow injury followed by aplasia and bone marrow remodeling, leading to impaired hematopoietic reserve and function (Box 3). Sympathetic nerves seem to promote the survival of key niche components leading to hematopoietic recovery¹, indicating that additional investigation into the specific stromal cells acted on by the sympathetic nerves may improve therapies aimed at increasing bone

marrow functionality. The development of approaches to radioprotect perivascular stromal cells and endothelial cells could also further improve hematopoietic reconstitution. Therapeutic delivery of cytokines including FGF, EGF and IFN- γ , repression of proapoptotic proteins such as PUMA, delivery of the antiapoptotic factor aPC110 or inhibition of regeneration-hindering pathways such as TGF- β might also aid in augmenting multilineage hematopoietic reconstitution. However, it remains unclear whether a ‘magic bullet’ promoting HSC expansion without impinging on self renewal exists.

Similarities among varying tissues containing stem cell niches, such as the intestinal crypt, hair and skin^{174–176}, may allow us to extrapolate benefits to hematopoietic maintenance and regeneration. Continued progress will undoubtedly lead to an enhanced understanding of the key players in niche function while technological advancements in imaging and construction of artificial ex vivo niches will provide exciting new possibilities for improved regenerative therapies and rejuvenation strategies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Lucas D, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. *Nat. Med.* 2013; 19:695–703. [PubMed: 23644514]
2. Pietras EM, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. *J. Exp. Med.* 2014; 211:245–262. [PubMed: 24493802]
3. Lymperi S, Ferraro F, Scadden DT. The HSC niche concept has turned 31. Has our knowledge matured? *Ann. NY Acad. Sci.* 2010; 1192:12–18. [PubMed: 20392212]
4. Wang LD, Wagers AJ. Dynamic niches in the origination and differentiation of haematopoietic stem cells. *Nat. Rev. Mol. Cell Biol.* 2011; 12:643–655. [PubMed: 21886187]
5. Warr MR, Pietras EM, Passegue E. Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 2011; 3:681–701.
6. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. *Nature.* 2014; 505:327–334. [PubMed: 24429631]
7. Adamo L, et al. Biomechanical forces promote embryonic haematopoiesis. *Nature.* 2009; 459:1131–1135. [PubMed: 19440194]
8. Shin JW, et al. Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells. *Cell Stem Cell.* 2014; 14:81–93. [PubMed: 24268694]
9. Passegué E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. *J. Exp. Med.* 2005; 202:1599–1611. [PubMed: 16330818]
10. Essers MA, et al. IFN α activates dormant haematopoietic stem cells in vivo. *Nature.* 2009; 458:904–908. [PubMed: 19212321]
11. Wilson A, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell.* 2008; 135:1118–1129. [PubMed: 19062086]
12. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN- γ in response to chronic infection. *Nature.* 2010; 465:793–797. [PubMed: 20535209]
13. Cao X, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. *Proc. Natl. Acad. Sci. USA.* 2011; 108:1609–1614. [PubMed: 21220327]

14. Özcan MA, İlhan O, Özcebe OI, Nalcaci M, Gulbas Z. Review of therapeutic options and the management of patients with myelodysplastic syndromes. *Expert Rev. Hematol.* 2013; 6:165–189. [PubMed: 23547866]
15. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. *Cell Stem Cell.* 2012; 10:120–136. [PubMed: 22305562]
16. Pereira CF, et al. Induction of a hemogenic program in mouse fibroblasts. *Cell Stem Cell.* 2013; 13:205–218. [PubMed: 23770078]
17. Riddell J, et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. *Cell.* 2014; 157:549–564. [PubMed: 24766805]
18. Sandler V, et al. Reprogramming human endothelial to hematopoietic cells requires vascular induction. *Nature.* 2014 Jul 2.
19. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation.* 1974; 17:331–340. [PubMed: 4150881]
20. Song J, et al. An in vivo model to study and manipulate the hematopoietic stem cell niche. *Blood.* 2010; 115:2592–2600. [PubMed: 20110425]
21. Sacchetti B, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell.* 2007; 131:324–336. [PubMed: 17956733]
22. Pinho S, et al. PDGFR α and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *J. Exp. Med.* 2013; 210:1351–1367. [PubMed: 23776077]
23. Méndez-Ferrer S, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature.* 2010; 466:829–834. [PubMed: 20703299]
24. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity.* 2006; 25:977–988. [PubMed: 17174120]
25. Greenbaum A, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature.* 2013; 495:227–230. [PubMed: 23434756]
26. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature.* 2012; 481:457–462. [PubMed: 22281595]
27. Park D, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. *Cell Stem Cell.* 2012; 10:259–272. [PubMed: 22385654]
28. Joseph C, et al. Deciphering hematopoietic stem cells in their niches: a critical appraisal of genetic models, lineage tracing, and imaging strategies. *Cell Stem Cell.* 2013; 13:520–533. [PubMed: 24209759]
29. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. *Nature.* 2013; 495:231–235. [PubMed: 23434755]
30. Kunisaki Y, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature.* 2013; 502:637–643. [PubMed: 24107994]
31. Mizoguchi T, et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Dev. Cell.* 2014; 29:340–349. [PubMed: 24823377]
32. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor– expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell Stem Cell.* 2014 Jun 19.
33. Nolan DJ, et al. Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. *Dev. Cell.* 2013; 26:204–219. [PubMed: 23871589]
34. Kobayashi H, et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. *Nat. Cell Biol.* 2010; 12:1046–1056. [PubMed: 20972423]
35. Krause DS, Scadden DT, Preffer FI. The hematopoietic stem cell niche— home for friend and foe? *Cytometry B Clin. Cytom.* 2013; 84:7–20.

36. Kennedy M, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature*. 1997; 386:488–493. [PubMed: 9087406]
37. Shalaby F, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature*. 1995; 376:62–66. [PubMed: 7596435]
38. Ono N, et al. Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. *Dev. Cell*. 2014; 29:330–339. [PubMed: 24823376]
39. Kiel MJ, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell*. 2005; 121:1109–1121. [PubMed: 15989959]
40. Doan PL, et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. *Nat. Med*. 2013; 19:295–304. [PubMed: 23377280]
41. Himburg HA, et al. Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. *Cell Reports*. 2012; 2:964–975. [PubMed: 23084748]
42. Hooper AT, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. *Cell Stem Cell*. 2009; 4:263–274. [PubMed: 19265665]
43. Zhang J, et al. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature*. 2003; 425:836–841. [PubMed: 14574412]
44. Calvi LM, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature*. 2003; 425:841–846. [PubMed: 14574413]
45. Liu Y, et al. Osterix-Cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. *PLoS ONE*. 2013; 8:e71318. [PubMed: 23951132]
46. Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. *Nature*. 2008; 452:442–447. [PubMed: 18256599]
47. Katayama Y, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell*. 2006; 124:407–421. [PubMed: 16439213]
48. Yamazaki S, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. *Cell*. 2011; 147:1146–1158. [PubMed: 22118468]
49. Chow A, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. *J. Exp. Med*. 2011; 208:261–271. [PubMed: 21282381]
50. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. *J. Exp. Med*. 2011; 208:251–260. [PubMed: 21282380]
51. Winkler IG, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. *Blood*. 2010; 116:4815–4828. [PubMed: 20713966]
52. Lucas D, et al. Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields. *Blood*. 2012; 119:3962–3965. [PubMed: 22422821]
53. Naveiras O, et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature*. 2009; 460:259–263. [PubMed: 19516257]
54. Miyamoto K, et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. *J. Exp. Med*. 2011; 208:2175–2181. [PubMed: 22006978]
55. Kollet O, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. *Nat. Med*. 2006; 12:657–664. [PubMed: 16715089]
56. Lin H. The stem-cell niche theory: lessons from flies. *Nat. Rev. Genet*. 2002; 3:931–940. [PubMed: 12459723]
57. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells*. 1978; 4:7–25. [PubMed: 747780]
58. Schajnovitz A, et al. CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. *Nat. Immunol*. 2011; 12:391–398. [PubMed: 21441933]
59. Pajcini KV, Speck NA, Pear WS. Notch signaling in mammalian hematopoietic stem cells. *Leukemia*. 2011; 25:1525–1532. [PubMed: 21647159]

60. Bigas A, Espinosa L. Hematopoietic stem cells: to be or Notch to be. *Blood*. 2012; 119:3226–3235. [PubMed: 22308291]
61. Oh P, et al. In vivo mapping of notch pathway activity in normal and stress hematopoiesis. *Cell Stem Cell*. 2013; 13:190–204. [PubMed: 23791481]
62. Varnum-Finney B, et al. Notch2 governs the rate of generation of mouse long- and short-term repopulating stem cells. *J. Clin. Invest.* 2011; 121:1207–1216. [PubMed: 21285514]
63. Maillard I, et al. Canonical Notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. *Cell Stem Cell*. 2008; 2:356–366. [PubMed: 18397755]
64. Mercher T, et al. Notch signaling specifies megakaryocyte development from hematopoietic stem cells. *Cell Stem Cell*. 2008; 3:314–326. [PubMed: 18786418]
65. Poulos MG, et al. Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. *Cell Reports*. 2013; 4:1022–1034. [PubMed: 24012753]
66. Mancini SJ, et al. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. *Blood*. 2005; 105:2340–2342. [PubMed: 15550486]
67. Lee SU, et al. LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance. *Blood*. 2013; 121:918–929. [PubMed: 23134786]
68. Oyama T, et al. Mastermind-like 1 (MamL1) and mastermind-like 3 (MamL3) are essential for Notch signaling in vivo. *Development*. 2011; 138:5235–5246. [PubMed: 22069191]
69. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. *Cell Stem Cell*. 2009; 4:27–36. [PubMed: 19128790]
70. Willert K, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature*. 2003; 423:448–452. [PubMed: 12717451]
71. Reya T, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. *Nature*. 2003; 423:409–414. [PubMed: 12717450]
72. Scheller M, et al. Hematopoietic stem cell and multilineage defects generated by constitutive β -catenin activation. *Nat. Immunol.* 2006; 7:1037–1047. [PubMed: 16951686]
73. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. *Nat. Immunol.* 2006; 7:1048–1056. [PubMed: 16951689]
74. Luis TC, et al. Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. *Blood*. 2009; 113:546–554. [PubMed: 18832654]
75. Fleming HE, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. *Cell Stem Cell*. 2008; 2:274–283. [PubMed: 18371452]
76. Cobas M, et al. β -catenin is dispensable for hematopoiesis and lymphopoiesis. *J. Exp. Med.* 2004; 199:221–229. [PubMed: 14718516]
77. Zhao C, et al. Loss of β -catenin impairs the renewal of normal and CML stem cells in vivo. *Cancer Cell*. 2007; 12:528–541. [PubMed: 18068630]
78. Koch U, et al. Simultaneous loss of β - and γ -catenin does not perturb hematopoiesis or lymphopoiesis. *Blood*. 2008; 111:160–164. [PubMed: 17855627]
79. Jeannot G, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of β -catenin and γ -catenin. *Blood*. 2008; 111:142–149. [PubMed: 17906078]
80. Staal FJ, Luis TC. Wnt signaling in hematopoiesis: crucial factors for selfrenewal, proliferation, and cell fate decisions. *J. Cell. Biochem.* 2010; 109:844–849. [PubMed: 20069555]
81. Nemeth MJ, Topol L, Anderson SM, Yang Y, Bodine DM. Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. *Proc. Natl. Acad. Sci. USA*. 2007; 104:15436–15441. [PubMed: 17881570]
82. Povinelli BJ, Nemeth MJ. Wnt5a regulates hematopoietic stem cell proliferation and repopulation through the Ryk receptor. *Stem Cells*. 2014; 32:105–115. [PubMed: 23939973]
83. Sugimura R, et al. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. *Cell*. 2012; 150:351–365. [PubMed: 22817897]
84. Luis TC, et al. Canonical Wnt signaling regulates hematopoiesis in a dosagedependent fashion. *Cell Stem Cell*. 2011; 9:345–356. [PubMed: 21982234]

85. Haug JS, et al. N-cadherin expression level distinguishes reserved versus primed states of hematopoietic stem cells. *Cell Stem Cell*. 2008; 2:367–379. [PubMed: 18397756]
86. Hosokawa K, et al. Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. *Cell Stem Cell*. 2010; 6:194–198. [PubMed: 20207221]
87. Kiel MJ, Acar M, Radice GL, Morrison SJ. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. *Cell Stem Cell*. 2009; 4:170–179. [PubMed: 19119091]
88. Greenbaum AM, Revollo LD, Woloszynek JR, Civitelli R, Link DC. Ncadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. *Blood*. 2012; 120:295–302. [PubMed: 22323481]
89. Bromberg O, et al. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. *Blood*. 2012; 120:303–313. [PubMed: 22596259]
90. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF- β 1. *Cell Stem Cell*. 2010; 6:265–278. [PubMed: 20207229]
91. Brenet F, Kermani P, Spektor R, Rafii S, Scandura JM. TGF β restores hematopoietic homeostasis after myelosuppressive chemotherapy. *J. Exp. Med*. 2013; 210:623–639. [PubMed: 23440043]
92. Miharada K, et al. Cripto regulates hematopoietic stem cells as a hypoxic-niche- related factor through cell surface receptor GRP78. *Cell Stem Cell*. 2011; 9:330–344. [PubMed: 21982233]
93. Arai F, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell*. 2004; 118:149–161. [PubMed: 15260986]
94. Istvanffy R, et al. Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. *Blood*. 2011; 118:2712–2722. [PubMed: 21791434]
95. Ghiaur G, et al. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling. *Proc. Natl. Acad. Sci. USA*. 2013; 110:16121–16126. [PubMed: 24043786]
96. Spoorendonk KM, et al. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. *Development*. 2008; 135:3765–3774. [PubMed: 18927155]
97. Nombela-Arrieta C, et al. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. *Nat. Cell Biol*. 2013; 15:533–543. [PubMed: 23624405]
98. Ellis SL, et al. The relationship between bone, hemopoietic stem cells, and vasculature. *Blood*. 2011; 118:1516–1524. [PubMed: 21673348]
99. Guezguez B, et al. Regional localization within the bone marrow influences the functional capacity of human HSCs. *Cell Stem Cell*. 2013; 13:175–189. [PubMed: 23910084]
100. Lo Celso C, et al. Live-animal tracking of individual hematopoietic stem/progenitor cells in their niche. *Nature*. 2009; 457:92–96. [PubMed: 19052546]
101. Lewandowski D, et al. In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. *Blood*. 2010; 115:443–452. [PubMed: 19797522]
102. Wang L, et al. Identification of a clonally expanding haematopoietic compartment in bone marrow. *EMBO J*. 2013; 32:219–230. [PubMed: 23188081]
103. Signer RA, Morrison SJ. Mechanisms that regulate stem cell aging and life span. *Cell Stem Cell*. 2013; 12:152–165. [PubMed: 23395443]
104. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. *Cell Stem Cell*. 2011; 9:298–310. [PubMed: 21982230]
105. Mauch P, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. *Int. J. Radiat. Oncol. Biol. Phys*. 1995; 31:1319–1339. [PubMed: 7713791]
106. Sokolov M, Neumann R. Lessons learned about human stem cell responses to ionizing radiation exposures: a long road still ahead of us. *Int. J. Mol. Sci*. 2013; 14:15695–15723. [PubMed: 23899786]
107. Becker D, et al. Response of human hematopoietic stem and progenitor cells to energetic carbon ions. *Int. J. Radiat. Biol*. 2009; 85:1051–1059. [PubMed: 19895282]

108. Katoh O, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. *Cancer Res.* 1998; 58:5565–5569. [PubMed: 9850095]
109. Geiger H, et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. *Nat. Med.* 2012; 18:1123–1129. [PubMed: 22729286]
110. Iwasaki H, Arai F, Kubota Y, Dahl M, Suda T. Endothelial protein C receptor-expressing hematopoietic stem cells reside in the perisinusoidal niche in fetal liver. *Blood.* 2010; 116:544–553. [PubMed: 20442369]
111. Johnson SM, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. *J. Clin. Invest.* 2010; 120:2528–2536. [PubMed: 20577054]
112. Marone M, et al. Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21. *Leuk. Lymphoma.* 2002; 43:51–57. [PubMed: 11908736]
113. Milyavsky M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. *Cell Stem Cell.* 2010; 7:186–197. [PubMed: 20619763]
114. Lange C, et al. Radiation rescue: mesenchymal stromal cells protect from lethal irradiation. *PLoS ONE.* 2011; 6:e14486. [PubMed: 21245929]
115. Jung H, et al. TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress. *Cell Metab.* 2013; 18:75–85. [PubMed: 23823478]
116. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell. Signal.* 2012; 24:981–990. [PubMed: 22286106]
117. Ito K, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat. Med.* 2006; 12:446–451. [PubMed: 16565722]
118. Yahata T, et al. Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. *Blood.* 2011; 118:2941–2950. [PubMed: 21734240]
119. Koh AJ, et al. An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. *Endocrinology.* 2011; 152:4525–4536. [PubMed: 22045660]
120. MacVittie TJ, Farese AM. Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure. *Mil. Med.* 2002; 167:68–70. [PubMed: 11873522]
121. Drouet M, et al. Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: longterm follow-up of hematopoiesis. *Blood.* 2004; 103:878–885. [PubMed: 14525791]
122. Hérodin F, Bourin P, Mayol JF, Lataillade JJ, Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma irradiation promotes survival. *Blood.* 2003; 101:2609–2616. [PubMed: 12468435]
123. Doan PL, et al. Tie2+ bone marrow endothelial cells regulate hematopoietic stem cell regeneration following radiation injury. *Stem Cells.* 2013; 31:327–337. [PubMed: 23132593]
124. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. *Cancer Res.* 1995; 55:5687–5692. [PubMed: 7585655]
125. Gerber HP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature.* 2002; 417:954–958. [PubMed: 12087404]
126. Zhao M, et al. FGF signaling facilitates postinjury recovery of mouse hematopoietic system. *Blood.* 2012; 120:1831–1842. [PubMed: 22802336]
127. de Bruin AM, Demirel O, Hooibrink B, Brandts CH, Nolte MA. Interferon- γ impairs proliferation of hematopoietic stem cells in mice. *Blood.* 2013; 121:3578–3585. [PubMed: 23487025]
128. Lam BS, Cunningham C, Adams GB. Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrow. *Blood.* 2011; 117:1167–1175. [PubMed: 21076044]

129. Sreeramkumar V, et al. Coordinated and unique functions of the E-selectin ligand ESL-1 during inflammatory and hematopoietic recruitment in mice. *Blood*. 2013; 122:3993–4001. [PubMed: 24106206]
130. Nakamura-Ishizu A, et al. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. *Blood*. 2012; 119:5429–5437. [PubMed: 22553313]
131. Smith-Berdan S, et al. Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. *Cell Stem Cell*. 2011; 8:72–83. [PubMed: 21211783]
132. Chow A, et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. *Nat. Med*. 2013; 19:429–436. [PubMed: 23502962]
133. Ramos P, et al. Macrophages support pathological erythropoiesis in polycythemia vera and β -thalassemia. *Nat. Med*. 2013; 19:437–445. [PubMed: 23502961]
134. Pitchford SC, Lodie T, Rankin SM. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. *Blood*. 2012; 120:2787–2795. [PubMed: 22653973]
135. Gars E, Raffi S. It takes 2 to thrombopoies in the vascular niche. *Blood*. 2012; 120:2775–2776. [PubMed: 23043022]
136. Dykstra B, Olthof S, Schreuder J, Ritsema M, de Haan G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. *J. Exp. Med*. 2011; 208:2691–2703. [PubMed: 22110168]
137. Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. *J. Exp. Med*. 2000; 192:1273–1280. [PubMed: 11067876]
138. Geiger H, Koehler A, Gunzer M. Stem cells, aging, niche, adhesion and Cdc42: a model for changes in cell-cell interactions and hematopoietic stem cell aging. *Cell Cycle*. 2007; 6:884–887. [PubMed: 17404508]
139. Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. *Nat. Med*. 1996; 2:1011–1016. [PubMed: 8782459]
140. Chen J, Astle CM, Harrison DE. Development and aging of primitive hematopoietic stem cells in BALB/cBy mice. *Exp. Hematol*. 1999; 27:928–935. [PubMed: 10340409]
141. Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. *Blood*. 2005; 106:1479–1487. [PubMed: 15827136]
142. Rossi DJ, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc. Natl. Acad. Sci. USA*. 2005; 102:9194–9199. [PubMed: 15967997]
143. Beerman I, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. *Proc. Natl. Acad. Sci. USA*. 2010; 107:5465–5470. [PubMed: 20304793]
144. Florian MC, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. *Cell Stem Cell*. 2012; 10:520–530. [PubMed: 22560076]
145. Miller JP, Allman D. Linking age-related defects in B lymphopoiesis to the aging of hematopoietic stem cells. *Semin. Immunol*. 2005; 17:321–329. [PubMed: 15979895]
146. Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. *Nat. Rev. Immunol*. 2013; 13:376–389. [PubMed: 23584423]
147. Xing Z, et al. Increased hematopoietic stem cell mobilization in aged mice. *Blood*. 2006; 108:2190–2197. [PubMed: 16741255]
148. Gekas C, Graf T. CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age. *Blood*. 2013; 121:4463–4472. [PubMed: 23564910]
149. Singh KP, et al. Loss of aryl hydrocarbon receptor promotes gene changes associated with premature hematopoietic stem cell exhaustion and development of a myeloproliferative disorder in aging mice. *Stem Cells Dev*. 2014; 23:95–106. [PubMed: 24138668]
150. Raffel GD, et al. Ott1 (Rbm15) has pleiotropic roles in hematopoietic development. *Proc. Natl. Acad. Sci. USA*. 2007; 104:6001–6006. [PubMed: 17376872]

151. Xiao N, et al. Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress. *Blood*. 2012; 119:4898–4907. [PubMed: 22490678]
152. Jeannot R, Cai Q, Liu H, Vu H, Kuo YH. Alcam regulates long-term hematopoietic stem cell engraftment and self-renewal. *Stem Cells*. 2013; 31:560–571. [PubMed: 23280653]
153. Satoh Y, et al. The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages. *Immunity*. 2013; 38:1105–1115. [PubMed: 23791645]
154. Geiger H, Zheng Y. Cdc42 and aging of hematopoietic stem cells. *Curr. Opin. Hematol.* 2013; 20:295–300. [PubMed: 23615056]
155. Florian MC, et al. A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing. *Nature*. 2013; 503:392–396. [PubMed: 24141946]
156. Miyamoto K, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. *Cell Stem Cell*. 2007; 1:101–112. [PubMed: 18371339]
157. Tothova Z, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell*. 2007; 128:325–339. [PubMed: 17254970]
158. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. *Blood*. 2007; 110:3056–3063. [PubMed: 17595331]
159. Norddahl GL, et al. Accumulating mitochondrial DNA mutations drive premature hematopoietic aging phenotypes distinct from physiological stem cell aging. *Cell Stem Cell*. 2011; 8:499–510. [PubMed: 21549326]
160. Wang J, et al. A differentiation checkpoint limits hematopoietic stem cell selfrenewal in response to DNA damage. *Cell*. 2012; 148:1001–1014. [PubMed: 22385964]
161. Mandal PK, Rossi DJ. DNA-damage-induced differentiation in hematopoietic stem cells. *Cell*. 2012; 148:847–848. [PubMed: 22385954]
162. Janzen V, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. *Nature*. 2006; 443:421–426. [PubMed: 16957735]
163. Köhler A, et al. Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long bones. *Blood*. 2009; 114:290–298. [PubMed: 19357397]
164. Siclari VA, et al. Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow. *Bone*. 2013; 53:575–586. [PubMed: 23274348]
165. Ergen AV, Boles NC, Goodell MA. Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing. *Blood*. 2012; 119:2500–2509. [PubMed: 22289892]
166. Villeda SA, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature*. 2011; 477:90–94. [PubMed: 21886162]
167. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. *Ciba Found. Symp.* 1988; 136:42–60. [PubMed: 3068016]
168. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. *Annu. Rev. Immunol.* 2013; 31:285–316. [PubMed: 23298209]
169. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]
170. Zheng J, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. *Cell Stem Cell*. 2011; 9:119–130. [PubMed: 21816363]
171. Csaszar E, et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. *Cell Stem Cell*. 2012; 10:218–229. [PubMed: 22305571]
172. Holst J, et al. Substrate elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells. *Nat. Biotechnol.* 2010; 28:1123–1128. [PubMed: 20890282]
173. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. *Blood*. 2011; 117:6083–6090. [PubMed: 21436068]
174. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science*. 2013; 340:1190–1194. [PubMed: 23744940]

175. Boehnke K, Falkowska-Hansen B, Stark HJ, Boukamp P. Stem cells of the human epidermis and their niche: composition and function in epidermal regeneration and carcinogenesis. *Carcinogenesis*. 2012; 33:1247–1258. [PubMed: 22461521]
176. Myung P, Ito M. Dissecting the bulge in hair regeneration. *J. Clin. Invest.* 2012; 122:448–454. [PubMed: 22293183]
177. Giralt S, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. *Biol. Blood Marrow Transplant.* 2014; 20:295–308. [PubMed: 24141007]
178. Cheuk DK. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. *World J. Transplant.* 2013; 3:99–112. [PubMed: 24392314]
179. Hess DA, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. *Biol. Blood Marrow Transplant.* 2007; 13:398–411. [PubMed: 17382247]
180. Pusic I, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. *Biol. Blood Marrow Transplant.* 2008; 14:1045–1056. [PubMed: 18721768]
181. Ramirez P, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood.* 2009; 114:1340–1343. [PubMed: 19571319]
182. Miller CL, Audet J, Eaves CJ. Ex vivo expansion of human and murine hematopoietic stem cells. *Methods Mol. Med.* 2002; 63:189–208. [PubMed: 21437809]
183. Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. *Blood.* 2005; 105:4314–4320. [PubMed: 15701724]
184. Jaroscak J, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. *Blood.* 2003; 101:5061–5067. [PubMed: 12595310]
185. Boitano AE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science.* 2010; 329:1345–1348. [PubMed: 20688981]
186. Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus repopulating ability of human CD34+CD38– cord blood cells. *J. Clin. Invest.* 2002; 110:1165–1174. [PubMed: 12393852]
187. Delaney C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. *Nat. Med.* 2010; 16:232–236. [PubMed: 20081862]
188. Genovese P, et al. Targeted genome editing in human repopulating haematopoietic stem cells. *Nature.* 2014; 510:235–240. [PubMed: 24870228]
189. Isern J, et al. Self-renewing human bone marrow mesospheres promote hematopoietic stem cell expansion. *Cell Reports.* 2013; 3:1714–1724. [PubMed: 23623496]
190. Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. *Nat. Commun.* 2014; 5:4240. [PubMed: 24967838]
191. Wei J, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. *Cancer Cell.* 2008; 13:483–495. [PubMed: 18538732]
192. Lane SW, et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. *Blood.* 2011; 118:2849–2856. [PubMed: 21765021]
193. Colmone A, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. *Science.* 2008; 322:1861–1865. [PubMed: 19095944]
194. Schepers K, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. *Cell Stem Cell.* 2013; 13:285–299. [PubMed: 23850243]
195. Hanoun M, et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. *Cell Stem Cell.* 2014 Jul 10.
196. Arranz L, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. *Nature.* 2014 Jun 22.

Debbie Maizels/Nature Publishing Group

Figure 1.

Figure 2.

Figure 3.

Figure 4.